Post your pictures and videos, add events to the calendar and update your blog. Post your pictures, add events to the calendar and more.
More
Post your pictures and videos, add events to the calendar and update your blog. Post your pictures, add events to the calendar and more.
More
|
WASHINGTON — The Food and Drug Administration says it has approved a new form of a best-selling breast cancer drug that targets tumor cells while sparing healthy ones.
The drug Kadcyla (kad-SY’-luh) from Roche combines the established drug Herceptin with a powerful chemotherapy and a third chemical linking the medicines together. The chemical keeps the drugs intact until they bind to a cancer cell, where the double-shot of medication is released.
The FDA approved the drug for about 20 percent of breast cancer patients who have a particular form of the disease. These patients have tumors that overproduce the protein HER-2.